{"id":"agn-210669","safety":{"commonSideEffects":[{"rate":null,"effect":"Hyperthermia or impaired temperature sensation"},{"rate":null,"effect":"Gastrointestinal effects"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"TRPV1 is a cation channel expressed on nociceptive nerve fibers that mediates pain sensation, particularly in response to heat, capsaicin, and inflammatory mediators. By blocking TRPV1, AGN-210669 reduces the transmission of pain signals from peripheral tissues to the central nervous system. This mechanism is being explored for chronic pain conditions where TRPV1-mediated signaling contributes to pain pathophysiology.","oneSentence":"AGN-210669 is a selective inhibitor of the transient receptor potential vanilloid 1 (TRPV1) channel that reduces pain signaling in sensory neurons.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T02:21:16.368Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic pain (specific indication under investigation in Phase 2)"}]},"trialDetails":[{"nctId":"NCT01291108","phase":"PHASE2","title":"Safety and Efficacy of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2011-04","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":125},{"nctId":"NCT00809848","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of AGN 210669 Ophthalmic Solution in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma","status":"COMPLETED","sponsor":"Allergan","startDate":"2009-02","conditions":"Ocular Hypertension, Glaucoma","enrollment":172},{"nctId":"NCT01001195","phase":"PHASE2","title":"Safety and Efficacy of Three Formulations of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution","status":"COMPLETED","sponsor":"Allergan","startDate":"2009-11","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":165}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"AGN-210669","genericName":"AGN-210669","companyName":"Allergan","companyId":"allergan","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AGN-210669 is a selective inhibitor of the transient receptor potential vanilloid 1 (TRPV1) channel that reduces pain signaling in sensory neurons. Used for Chronic pain (specific indication under investigation in Phase 2).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}